Acta Cancerológica.     Vol. 31 •  Nº 1 •  Mayo 2002



1. Vita V, Hellman S, Rosemberg S. Cancer, principles and practice of Oncology. Ed J.B. Lippincott Company. Philadelphia. 2000

2. Cortés Funes H, Díaz Rubio E, García Conde J. Oncología Médica Ed. Nova Sidonia. Madrid 1999.

3. Rubini C, Amorín E, Rojas V. Aspectos generales del Cáncer de Pulmón. INEN. 1998.

4. Vaslamatzis M, Pladetakl V, Rontoyami D, Koutrelini H, Alexopoulos C. Demograpffic, clinical and histological characteristics in SCLC. Proc Am Soc Clin Oncol 1999; 18: A2030.

5. Current perspectives in the treatment of Lung Cancer. Oncology. January 1998; Vol 12, No 1, Suppl 2: 5-49.

6. Hirsch F, Osterlind K, Hansen H. The prognostic significance of histopathologic subtyping of SCLC according to the classification of the WHO: a study of 375 consecutive patients. Cancer 1983; 52:2144.

7. Patz E. Imaging Bronchogenic Carcinoma. Chest 2000; 117: 90S-95S.

8. Albain KS, Crowley J, Leblane M. Determinants of improved outcome in SCLC: an analysis of the 2580 SWOG data base. J Clin Oncol 1990;8:1563.

9. Johnson D. Management of SCLC. Current status of the art. Chest 1999; 116: 525S-530S.

10. SCLC: Advances in the managemente of limited disease. American Society of Clinical Oncology. Fall Educational Book. May 1999; 233-246.

11. Kelly K. New chemotherapy agents for SCLC. Chest 2000; 117: 156S-162S.

12. Bonomi P. Review of selected randomized trials in SCLC. Semin Oncol 1998; 25 (Suppl 9): 70-78.

13. Postmus P, Schramel F, Smit E. Evaluation of new drugs in SCLC: the activity of Gemcitabine. Semin Oncol 1992; 25 (Suppl 9): 79-82.

14. Bunn P, Carney D. Overview of chemothrapy for SCLC. Semin Oncol 1997; 24 (Suppl 7): S7-69-S7-74

15. Rabman I, Thödtmann R, Depenbrock H, Blatter J. Gemcitabine and VP-16 in SCLC. Phase I and II trials. Semin Oncol 1997;24 (Suppl 7): S7-75-S7-78.

16. Van der Lee I, Postmus P, Smit E, et al. The activity of Gemcitabine in patients with resistant SCLC; a phase II study. Proc Annu Meet Am Soc Clin Oncol 1999;I8:A1835.

17. Masters G, Declerck L, Blanke C, et al. Gemcitabine in refractary or relapsed SCLC-E1597: an ECOG phase II trial. Proc Annu Meet Am Soc Clin Oncol 2000; 19:A2070.

18. Ardizzoni A, Grossi F. Update on the treatment of SCLC. ESMO Educational Book. 2000: 101-108.

19. Warde P, Payne D. Thoracic irradiation improve survival and local control in limited-stage SCLC. J Clin Oncol 1992; 10:890-895.

20. Jeremic B, Shibamoto Y, Nicolic N, et al. Role for radiation therapy in the combined-modality treatment of patients with extensive disease SCLC: Arandomized study. J Clin Oncol 17: 2092-2099,1999.

21. Arriagada R, Auperin A, Pignon J, et al. Prophylactic cranial irradiation overview in patients with SCLC in complete remission. Proc Am Soc Clin Oncol 1998; 17:457 (abstract 1758).

Volver al Artículo